trial

Confirmatory Study of DSP-5423P in Patients With Schizophrenia

NCTId NCT02287584
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 580 (actual)
Sponsored by Sumitomo Pharmaceuticals America
Primary completion 2018-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
580 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2014-12
Primary completion
2018-12
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
DSP-5423P 40mgDSP-5423P 80mgDSP-5423P Active-to-Flex

Sponsors

Sumitomo Pharmaceuticals AmericaLead Sponsor

Investigators

1
Director, Drug Development DivisionStudy Director

Sites

8 total
Beijing, Etc., ChinaTokyo Etc., JapanKuala Lumpur, Etc., MalaysiaManila, Etc., PhilippinesSmolensk, Etc, RussiaSeoul, Etc., South KoreaTaipei, Etc., TaiwanPoltava, Etc, Ukraine

Linked catalysts

1
Confirmatory Study of DSP-5423P in Patients With Schizophrenia — primary completion2018-12

Facts & assertions

4 sourced
Enrollment
580
Phase
PHASE3
Primary Completion Date
2018-12
Status
COMPLETED
relationships
The graph out of here
drug
DSP-5423P 40mg
drug
DSP-5423P 80mg
drug
DSP-5423P Active-to-Flex
drug
lead_sponsor
Sumitomo Pharmaceuticals America
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Director, Drug Development Division
person